Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Seong Hye | - |
dc.contributor.author | Lee, Dae-Hee | - |
dc.contributor.author | Kim, Jung Lim | - |
dc.contributor.author | Kim, Bo Ram | - |
dc.contributor.author | Na, Yoo Jin | - |
dc.contributor.author | Jo, Min Jee | - |
dc.contributor.author | Jeong, Yoon A. | - |
dc.contributor.author | Lee, Suk-Young | - |
dc.contributor.author | Lee, Sun Il | - |
dc.contributor.author | Lee, Yong Yook | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.date.accessioned | 2021-09-03T20:04:47Z | - |
dc.date.available | 2021-09-03T20:04:47Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09-13 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87529 | - |
dc.description.abstract | Metformin is an anti-diabetic drug with a promising anti-cancer potential. In this study, we show that subtoxic doses of metformin effectively sensitize human colorectal cancer (CRC) cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), which induces apoptosis. Metformin alone did not induce apoptosis, but significantly potentiated TRAIL-induced apoptosis in CRC cells. CRC cells treated with metformin and TRAIL showed activation of the intrinsic and extrinsic pathways of caspase activation. We attempted to elucidate the underlying mechanism, and found that metformin significantly reduced the protein levels of myeloid cell leukemia 1 (Mcl-1) in CRC cells and, the overexpression of Mcl-1 inhibited cell death induced by metformin and/or TRAIL. Further experiments revealed that metformin did not affect mRNA levels, but increased proteasomal degradation and protein stability of Mcl-1. Knockdown of Mule triggered a significant decrease of Mcl-1 polyubiquitination. Metformin caused the dissociation of Noxa from Mcl-1, which allowed the binding of the BH3-containing ubiquitin ligase Mule followed by Mcl-1ubiquitination and degradation. The metformin-induced degradation of Mcl-1 required E3 ligase Mule, which is responsible for the polyubiquitination of Mcl-1. Our study is the first report indicating that metformin enhances TRAIL-induced apoptosis through Noxa and favors the interaction between Mcl-1 and Mule, which consequently affects Mcl-1 ubiquitination. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.subject | RANDOMIZED PHASE-III | - |
dc.subject | DEATH RECEPTORS 4 | - |
dc.subject | DOWN-REGULATION | - |
dc.subject | BREAST-CANCER | - |
dc.subject | UP-REGULATION | - |
dc.subject | CLINICAL-SIGNIFICANCE | - |
dc.subject | MEDIATED APOPTOSIS | - |
dc.subject | 1ST-LINE THERAPY | - |
dc.subject | GLIOMA-CELLS | - |
dc.subject | IN-VIVO | - |
dc.title | Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Dae-Hee | - |
dc.contributor.affiliatedAuthor | Kim, Bo Ram | - |
dc.contributor.affiliatedAuthor | Lee, Sun Il | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.18632/oncotarget.11147 | - |
dc.identifier.scopusid | 2-s2.0-84991383153 | - |
dc.identifier.wosid | 000387153900058 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.7, no.37, pp.59503 - 59518 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 7 | - |
dc.citation.number | 37 | - |
dc.citation.startPage | 59503 | - |
dc.citation.endPage | 59518 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | DEATH RECEPTORS 4 | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | CLINICAL-SIGNIFICANCE | - |
dc.subject.keywordPlus | MEDIATED APOPTOSIS | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | GLIOMA-CELLS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordAuthor | metformin | - |
dc.subject.keywordAuthor | TRAIL | - |
dc.subject.keywordAuthor | CRC | - |
dc.subject.keywordAuthor | Mcl-1 | - |
dc.subject.keywordAuthor | Noxa | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.